Therapeutic Controversies: Tumor Necrosis Factor α Inhibitors in Ankylosing Spondylitis

Rheumatic Disease Clinics of North America

Volumn 38, Issue 3, 2012, Pages 613-633

  Song, I H ^a   Maksymowych, W P ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Ankylosing spondylitis; Efficacy; Extraarticular manifestations; Immunogenicity; Magnetic resonance imaging; Radiographic progression; TNF inhibitor; Uveitis

Indexed keywords

ADALIMUMAB; CHIMERIC ANTIBODY; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; ANTIBODY DETECTION; AREA UNDER THE CURVE; CLINICAL FEATURE; CLINICAL PRACTICE; CROHN DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTERITIS; ENTHESITIS; HUMAN; IMMUNOGENICITY; IRIDOCYCLITIS; LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MEDICAL SOCIETY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SUBSTITUTION; HUMANS; INFLAMMATION; JOINTS; MAGNETIC RESONANCE IMAGING; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867803600     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2012.08.004     Document Type: Review

References (124)

1. van der Heijde D., Sieper J., Maksymowych W., et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011, 70(6):905-908.
2. van der Heijde D., Dijkmans B., Geusens P., et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005, 52(2):582-591.
3. van der Heijde D., Kivitz A., Schiff M.H., et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006, 54(7):2136-2146.
4. Davis J.C., Van Der Heijde D., Braun J., et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003, 48(11):3230-3236.
5. Inman R.D., Davis J.C., Heijde D., et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008, 58(11):3402-3412.
6. Lee J.H., Jun J.B., Jung S., et al. Higher prevalence of peripheral arthritis among ankylosing spondylitis patients. J Korean Med Sci 2002, 17(5):669-673.
7. Khan M.A. Update on spondyloarthropathies. Ann Intern Med 2002, 136(12):896-907.
8. Elewaut D., Matucci-Cerinic M. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology (Oxford) 2009, 48(9):1029-1035.
9. Vander Cruyssen B., Ribbens C., Boonen A., et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis 2007, 66(8):1072-1077.
10. Rosenbaum J.T. Effect of etanercept on iritis in patients with ankylosing spondylitis. Arthritis Rheum 2004, 50(11):3736-3737.
11. Smith J.R., Levinson R.D., Holland G.N., et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001, 45(3):252-257.
12. Monnet D., Moachon L., Dougados M., et al. Severe uveitis in an HLA-B27-positive patient with ankylosing spondylitis. Nat Clin Pract Rheumatol 2006, 2(7):393-397.
13. Coates L.C., McGonagle D.G., Bennett A.N., et al. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis. Ann Rheum Dis 2008, 67(5):729-730.
14. Wendling D., Paccou J., Berthelot J.M., et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum 2011, 41(3):503-510.
15. Guignard S., Gossec L., Salliot C., et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006, 65(12):1631-1634.
16. Cobo-Ibanez T., del Carmen Ordonez M., Munoz-Fernandez S., et al. Do TNF-blockers reduce or induce uveitis?. Rheumatology (Oxford) 2008, 47(5):731-732.
17. Lim L.L., Fraunfelder F.W., Rosenbaum J.T. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007, 56(10):3248-3252.
18. Rudwaleit M., Rodevand E., Holck P., et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009, 68(5):696-701.
19. Braun J., Baraliakos X., Listing J., et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005, 52(8):2447-2451.
20. Sieper J., Koenig A., Baumgartner S., et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 2010, 69(1):226-229.
21. Van den Bosch F., Kruithof E., De Vos M., et al. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000, 356(9244):1821-1822.
22. Generini S., Giacomelli R., Fedi R., et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 2004, 63(12):1664-1669.
23. Humira® (Adalimumab) Summary of Product Characteristics (SPC). February 2008.
24. Marzo-Ortega H., McGonagle D., O'Connor P., et al. Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis 2003, 62(1):74-76.
25. Enbrel® (Etanercept) Summary of Product Characteristics (SPC). July 2008.
26. Sandborn W.J., Hanauer S.B., Katz S., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121(5):1088-1094.
27. Song I.H., Appel H., Haibel H., et al. New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept. J Rheumatol 2008, 35(3):532-536.
28. Remicade® (Infliximab) Summary of Product Characteristics (SPC). August 2008.
29. van der Heijde D., Calin A., Dougados M., et al. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol 1999, 26(4):951-954.
30. Rudwaleit M., Landewe R., van der Heijde D., et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009, 68(6):770-776.
31. Dougados M., van der Linden S., Juhlin R., et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991, 34(10):1218-1227.
32. Rudwaleit M., Haibel H., Baraliakos X., et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 2009, 60(3):717-727.
33. Mander M., Simpson J.M., McLellan A., et al. Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 1987, 46(3):197-202.
34. Dawes P.T. Stoke ankylosing spondylitis spine score. J Rheumatol 1999, 26(4):993-996.
35. Gorman J.D., Sack K.E., Davis J.C. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002, 346(18):1349-1356.
36. Heuft-Dorenbosch L., Spoorenberg A., van Tubergen A., et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003, 62(2):127-132.
37. Brandt J., Khariouzov A., Listing J., et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003, 48(6):1667-1675.
38. Maksymowych W.P., Mallon C., Morrow S., et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis 2009, 68(6):948-953.
39. Sieper J., Van der Heijde D., Dougados M., et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised, placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2012, [Epub ahead of print].
40. Dougados M., Combe B., Braun J., et al. A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. Ann Rheum Dis 2010, 69(8):1430-1435.
41. Song I.H., Hermann K., Haibel H., et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 2011, 70(4):590-596.
42. Weber U., Lambert R.G., Rufibach K., et al. Anterior chest wall inflammation by whole-body magnetic resonance imaging in patients with spondyloarthritis: lack of association between clinical and imaging findings in a cross-sectional study. Arthritis Res Ther 2012, 14(1):R3.
43. Navarro-Compan V., Moreira V., Ariza-Ariza R., et al. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin Rheumatol 2011, 30(7):993-996.
44. Lee J., Noh J.W., Hwang J.W., et al. Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis. Clin Rheumatol 2010, 29(10):1149-1154.
45. Lee S.H., Lee Y.A., Hong S.J., et al. Etanercept 25 mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients. Clin Rheumatol 2008, 27(2):179-181.
46. Paccou J., Bacle-Boutry M.A., Solau-Gervais E., et al. Dosage adjustment of anti-tumor necrosis factor-alpha inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice. J Rheumatol 2012, 39(7):1418-1423.
47. Baraliakos X., Listing J., Rudwaleit M., et al. Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol 2007, 34(3):510-515.
48. Brandt J., Listing J., Haibel H., et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford) 2005, 44(3):342-348.
49. Haibel H., Rudwaleit M., Listing J., et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008, 58(7):1981-1991.
50. Ash R., Barkham N., McGonagle D.G., et al. Long term results of a remission induction approach to early axial spondyloarthritis: still looking for the window of opportunity. Arthritis Rheum 2011, 63(Suppl 10):S503.
51. Song I.H., Althoff C.E., Haibel H., et al. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Ann Rheum Dis 2012, 71(7):1212-1215.
52. Anderson J.J., Baron G., van der Heijde D., et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001, 44(8):1876-1886.
53. Machado P., Landewe R., Lie E., et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011, 70(1):47-53.
54. Navarro-Sarabia F., Fernandez-Sueiro J.L., Torre-Alonso J.C., et al. High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). Rheumatology (Oxford) 2011, 50(10):1828-1837.
55. Bartelds G.M., Krieckaert C.L., Nurmohamed M.T., et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011, 305(14):1460-1468.
56. Arends S., Lebbink H.R., Spoorenberg A., et al. The formation of autoantibodies and antibodies to TNF-alpha blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol 2010, 28(5):661-668.
57. de Vries M.K., Wolbink G.J., Stapel S.O., et al. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation. Ann Rheum Dis 2007, 66(1):133-134.
58. de Vries M.K., Brouwer E., van der Horst-Bruinsma I.E., et al. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis 2009, 68(11):1787-1788.
59. de Vries M.K., van der Horst-Bruinsma I.E., Nurmohamed M.T., et al. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 2009, 68(4):531-535.
60. Emi Aikawa N., de Carvalho J.F., Artur Almeida Silva C., et al. Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 2010, 38(2-3):82-89.
61. Plasencia C., Pascual-Salcedo D., Nuno L., et al. Influence of immunogenicity on the efficacy of long-term treatment of spondyloarthritis with infliximab. Ann Rheum Dis 2012.
62. Ducourau E., Mulleman D., Paintaud G., et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther 2011, 13(3):R105.
63. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007, 66(7):921-926.
64. Maini R.N., Breedveld F.C., Kalden J.R., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41(9):1552-1563.
65. Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362(15):1383-1395.
66. Li E.K., Griffith J.F., Lee V.W., et al. Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Rheumatology (Oxford) 2008, 47(9):1358-1363.
67. Breban M., Ravaud P., Claudepierre P., et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 2008, 58(1):88-97.
68. Heiberg M.S., Koldingsnes W., Mikkelsen K., et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008, 59(2):234-240.
69. Mulleman D., Lauferon F., Wendling D., et al. Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study. Arthritis Res Ther 2011, 13(3):R82.
70. Rudwaleit M., Baraliakos X., Listing J., et al. Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Ann Rheum Dis 2005, 64(9):1305-1310.
71. Lambert R.G., Salonen D., Rahman P., et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2007, 56(12):4005-4014.
72. Maksymowych W.P., Salonen D., Inman R.D., et al. Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study. J Rheumatol 2010, 37(8):1728-1734.
73. Baraliakos X., Listing J., Rudwaleit M., et al. The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther 2008, 10(5):R104.
74. van der Heijde D., Machado P., Braun J., et al. MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. Ann Rheum Dis 2012, 71(3):369-373.
75. Maksymowych W.P., Chiowchanwisawakit P., Clare T., et al. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 2009, 60(1):93-102.
76. Chiowchanwisawakit P., Lambert R.G., Conner-Spady B., et al. Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum 2011, 63(8):2215-2225.
77. Pedersen S.J., Chiowchanwisawakit P., Lambert R.G., et al. Resolution of inflammation following treatment of ankylosing spondylitis is associated with new bone formation. J Rheumatol 2011, 38(7):1349-1354.
78. Maksymowych W.P., Morency N., Conner-Spady B., et al. Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification. Ann Rheum Dis 2012, [Epub ahead of print].
79. Maksymowych W.P. Disease modification in ankylosing spondylitis. Nat Rev Rheumatol 2010, 6(2):75-81.
80. Chiowchanwisawakit P., Lambert R.G., Maksymowych W. What is the association between inflammation and focal fat infiltration in AS and does treatment matter?. Ann Rheum Dis 2010, 69(Suppl 3):262.
81. Song I.H., Hermann K.G., Haibel H., et al. Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48. Ann Rheum Dis 2011, 70(7):1257-1263.
82. Wanders A., Heijde D., Landewe R., et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005, 52(6):1756-1765.
83. Poddubnyy D., Rudwaleit M., Haibel H., et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012, [Epub ahead of print].
84. Kroon F., Landewé R., Dougados M., van der Heijde D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Annals Rheum Dis 2012, [Epub ahead of print].
85. Dadoun S., Geri G., Paternotte S., et al. Switching between tumour necrosis factor blockers in spondyloarthritis: a retrospective monocentre study of 222 patients. Clin Exp Rheumatol 2011, 29(6):1010-1013.
86. Delaunay C., Farrenq V., Marini-Portugal A., et al. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. J Rheumatol 2005, 32(11):2183-2185.
87. Cantini F., Niccoli L., Benucci M., et al. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. Arthritis Rheum 2006, 55(5):812-816.
88. Coates L.C., Cawkwell L.S., Ng N.W., et al. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology (Oxford) 2008, 47(6):897-900.
89. Conti F., Ceccarelli F., Marocchi E., et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis 2007, 66(10):1393-1397.
90. Pradeep D.J., Keat A.C., Gaffney K., et al. Switching anti-TNF therapy in ankylosing spondylitis. Rheumatology (Oxford) 2008, 47(11):1726-1727.
91. Rudwaleit M., Van den Bosch F., Kron M., et al. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther 2010, 12(3):R117.
92. Lie E., van der Heijde D., Uhlig T., et al. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis 2011, 70(1):157-163.
93. Rudwaleit M., van der Heijde D., Landewe R., et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009, 68(6):777-783.
94. Glintborg B., Ostergaard M., Krogh N., et al. Clinical response, drug survival and predictors thereof in 432 patients with ankylosing spondylitis switching anti tumor necrosis factor α therapy: results form the Danish nationwide DANBIO registry. Ann Rheum Dis 2012, 71(Suppl 3):111.
95. Song I.H., Poddubnyy D. New treatment targets in ankylosing spondylitis and other spondyloarthritides. Curr Opin Rheumatol 2011, 23(4):346-351.
96. Rudwaleit M., Listing J., Brandt J., et al. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004, 63(6):665-670.
97. Rudwaleit M., Claudepierre P., Wordsworth P., et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009, 36(4):801-808.
98. Barkham N., Keen H.I., Coates L.C., et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 2009, 60(4):946-954.
99. Brandt J., Haibel H., Cornely D., et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000, 43(6):1346-1352.
100. Barkham N., Kong K.O., Tennant A., et al. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis. Rheumatology (Oxford) 2005, 44(10):1277-1281.
101. Cohen J.D., Cunin P., Farrenq V., et al. Estimation of the Bath Ankylosing Spondylitis Disease Activity Index cutoff for perceived symptom relief in patients with spondyloarthropathies. J Rheumatol 2006, 33(1):79-81.
102. Maksymowych W.P., Richardson R., Mallon C., et al. Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis. Arthritis Rheum 2007, 57(1):133-139.
103. Kiltz U., Baraliakos X., Karakostas P., et al. How much inflammation do patients with axial spondyloarthritis have who report low levels of disease activity? A prospective cohort study. Ann Rheum Dis 2011, 70(Suppl 3):521.
104. Breban M., Vignon E., Claudepierre P., et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford) 2002, 41(11):1280-1285.
105. Heiberg M.S., Lie E., Van der Heijde D., et al. A substantial proportioin of AS patients respond to TNF inhibitors despite not fulfilling the criteria for initiating anti-TNF therapy according to the ASAS/EULAR recommendations. Ann Rheum Dis 2009, 68(Suppl 3):631.
106. Maksymowych W.P., Gladman D., Rahman P., et al. The Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis: a national multidisciplinary stakeholder project. J Rheumatol 2007, 34(11):2273-2284.
107. Colbert R.A., Cronstein B.N. Biosimilars: the debate continues. Arthritis Rheum 2011, 63(10):2848-2850.
108. Park W., Hrycaj P., Kovalenko V., et al. Randomized, double-blind, phase 1 study demonstrates equivalence in pharmacokinetics, safety, and efficacy of CT-P13 and infliximab in patients with ankylosing spondylitis. Ann Rheum Dis 2012, 71(Suppl3):111.
109. Dranitsaris G., Amir E., Dorward K. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations. Drugs 2011, 71(12):1527-1536.
110. Mellstedt H., Niederwieser D., Ludwig H. The challenge of biosimilars. Ann Oncol 2008, 19(3):411-419.
111. Roger S.D. Biosimilars: current status and future directions. Expert Opin Biol Ther 2010, 10(7):1011-1018.
112. Keystone E.C. Does anti-tumor necrosis factor-alpha therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data. J Rheumatol 2011, 38(8):1552-1562.
113. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295(19):2275-2285.
114. Alonso-Ruiz A., Pijoan J.I., Ansuategui E., et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008, 9:52.
115. Leombruno J.P., Einarson T.R., Keystone E.C. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009, 68(7):1136-1145.
116. Wolfe F., Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007, 56(9):2886-2895.
117. Dixon W.G., Watson K.D., Lunt M., et al. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 2010, 62(6):755-763.
118. Strangfeld A., Hierse F., Rau R., et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010, 12(1):R5.
119. Geborek P., Bladstrom A., Turesson C., et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005, 64(5):699-703.
120. Askling J., Baecklund E., Granath F., et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009, 68(5):648-653.
121. Askling J., van Vollenhoven R.F., Granath F., et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?. Arthritis Rheum 2009, 60(11):3180-3189.
122. Askling J., Klareskog L., Blomqvist P., et al. Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis 2006, 65(9):1184-1187.
123. Mariette X., Tubach F., Bagheri H., et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 2010, 69(2):400-408.
124. Askling J., Fahrbach K., Nordstrom B., et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011, 20(2):119-130.